N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Poststroke Depression in Hemorrhagic Stroke
Stroke Hemorrhagic · Depression
Primary: Depression — 12.33; 6 units on a scale
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
N/A N=129 Stroke Ready: A Stroke Preparedness Brief Intervention
Stroke
Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Phase 2 N=81 Bolus of Saline in Stroke
Ischemic Stroke
Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…
N/A N=1,509 Stroke Ready - Optimizing Acute Stroke Care
Stroke, Acute · Stroke
Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients
Phase 1 N=60 Antihypertensive Treatment in Acute Cerebral Hemorrhage
Intracerebral Hemorrhage · Hypertension · Stroke
Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
Phase 2 N=42 Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
Subarachnoid Hemorrhage
Primary: Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk — .34; .30 mL/100 g/min
N/A N=2,839 The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
Intracerebral Hemorrhage · Stroke · Hypertension
Primary: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) — 719; 785 participants
Phase 2 N=15 Beta-hCG + Erythropoietin in Acute Stroke
Acute Stroke
Primary: Safety — 0 participants
N/A N=284 Stroke Swallowing Screening Tool Validation
Cerebrovascular Disorders · Deglutition Disorders
Primary: Sensitivity of Screening Items — 37.9; 3.5; 62.1; 10.3 percentage of agreement
Phase 2 N=120 Blood Pressure After Endovascular Stroke Therapy-II
Acute Stroke · Endovascular Thrombectomy
Primary: Final Infarct Volume — 46.4; 50.7; 32.4 Cubic Centimeters
Phase 3 N=499 Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
Intracerebral Hemorrhage
Primary: Dichotomized, Adjudicated Modified Rankin Scale Score 0-3 vs. 4-6 at 365 Days Post Ictus (Adjusted) — 110; 100; 139; 140 Participants — p=0.73
N/A N=4,071 China Antihypertensive Trial in Acute Ischemic Stroke
Ischemic Stroke
Primary: A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. — 681; 683 participants
Phase 2 N=3 Histamine Glutamate Antagonism in Stroke
Acute Cerebrovascular Accident · Cerebral Edema
Primary: Modified Rankin Score
N/A N=83 Stroke Telemedicine Outpatient Prevention Program for Blood Pressure Reduction
Stroke Prevention · Blood Pressure · Telemedicine
Primary: Daytime Ambulatory Systolic Blood Pressure — 123.6; 128.3 millimeters of mercury (mmHg)
Phase 3 N=88 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Transient Ischemic Attack · Stroke · Atrial Fibrillation
Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants
Phase 2 N=92 The Spot Sign for Predicting and Treating ICH Growth Study
Intracerebral Hemorrhage
Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
N/A N=10 A Study to Test the SENSE Device in Patients With Intracranial Hemorrhage
Intracerebral Hemorrhage · Stroke, Acute · Stroke Hemorrhagic
Primary: Number of Patients With Serious Device-related Adverse Events — 0 Participants
Phase 3 N=35 Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
Hypertension · Hemorrhage
Primary: Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine — 5.5 minutes
N/A N=30 Stroke Education Intervention Trial - Pilot
Ischemic Stroke · Intracranial Hemorrhage · Transient Ischemic Attack
Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
N/A N=222 Stroke Team Remote Evaluation Using a Digital Observation Camera
Stroke
Primary: Appropriateness of Decision to Treat or Not Treat With Thrombolytics — 98; 82 percentage of participants
Phase 2 N=38 CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial
Stroke
Primary: Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain — 0 participants
Phase 2 N=163 Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Chronic Ischemic Stroke
Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743
Phase 2 N=241 Normal Saline Infusion for Stroke After Intravenous Thrombolysis
Brain Infarct
Primary: Number of Participants With 90-day Favorable Outcome — 106; 93 Participants